TD 6301
Latest Information Update: 23 Nov 2016
At a glance
- Originator Theravance
- Class Urologics
- Mechanism of Action Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 12 May 2006 Discontinued - Phase-I for Overactive bladder in USA (unspecified route)
- 15 Apr 2004 Phase-I clinical trials in Overactive bladder in USA (unspecified route)